Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anabolism Versus Antiresorption: A Quadruple Labeling Histomorphometry Study to Compare the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women With Osteoporosis

NCT01753856 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01753856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01753856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anabolism Versus Antiresorption: A Quadruple Labeling Histomorphometry Study to Compare the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women With Osteoporosis
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2013
Completion date
June 30, 2014
Enrollment
69 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis